{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T12:35:00Z","timestamp":1756384500212,"version":"3.41.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,10,21]],"date-time":"2016-10-21T00:00:00Z","timestamp":1477008000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000071","name":"NICHD\/NIH","doi-asserted-by":"publisher","award":["K08 HD070957"],"award-info":[{"award-number":["K08 HD070957"]}],"id":[{"id":"10.13039\/100000071","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Genes & Diseases"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.gendis.2016.10.002","type":"journal-article","created":{"date-parts":[[2016,10,26]],"date-time":"2016-10-26T07:01:25Z","timestamp":1477465285000},"page":"252-256","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Immune-related endocrine disorders in novel immune checkpoint inhibition therapy"],"prefix":"10.1016","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4363-1139","authenticated-orcid":false,"given":"Le","family":"Min","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.gendis.2016.10.002_bib1","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"10","key":"10.1016\/j.gendis.2016.10.002_bib2","doi-asserted-by":"crossref","first-page":"5784","DOI":"10.4049\/jimmunol.162.10.5784","article-title":"Lymphoproliferative disorder in CTLA-4 knockout mice is characterized by CD28-regulated activation of Th2 responses","volume":"162","author":"Khattri","year":"1999","journal-title":"J Immunol"},{"issue":"10","key":"10.1016\/j.gendis.2016.10.002_bib3","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1093\/intimm\/10.10.1563","article-title":"Immunological studies on PD-1 deficient mice: implication of PD-1 as a negative regulator for B cell responses","volume":"10","author":"Nishimura","year":"1998","journal-title":"Int Immunol"},{"issue":"2","key":"10.1016\/j.gendis.2016.10.002_bib4","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1046\/j.0818-9641.2003.01151.x","article-title":"Cancer immunotherapy: the past, the present and the future","volume":"81","author":"Parish","year":"2003","journal-title":"Immunol Cell Biol"},{"issue":"8","key":"10.1016\/j.gendis.2016.10.002_bib5","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"issue":"6165","key":"10.1016\/j.gendis.2016.10.002_bib6","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1126\/science.342.6165.1432","article-title":"Breakthrough of the year 2013. Cancer immunotherapy","volume":"342","author":"Couzin-Frankel","year":"2013","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.gendis.2016.10.002_bib7","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.gendis.2016.10.002_bib8","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/nrclinonc.2016.58","article-title":"Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination","volume":"13","author":"Boutros","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"10.1016\/j.gendis.2016.10.002_bib9","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s11102-009-0193-z","article-title":"Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes","volume":"13","author":"Dillard","year":"2010","journal-title":"Pituitary"},{"issue":"4","key":"10.1016\/j.gendis.2016.10.002_bib10","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1158\/1078-0432.CCR-14-2353","article-title":"Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study","volume":"21","author":"Min","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.gendis.2016.10.002_bib11","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1210\/jc.2014-2306","article-title":"Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma","volume":"99","author":"Faje","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.gendis.2016.10.002_bib12","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1530\/ERC-13-0499","article-title":"Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution","volume":"21","author":"Ryder","year":"2014","journal-title":"Endocr Relat Cancer"},{"issue":"3","key":"10.1016\/j.gendis.2016.10.002_bib13","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1080\/02688690120057664","article-title":"Lymphocytic and granulocytic hypophysitis: a single centre experience","volume":"15","author":"Buxton","year":"2001","journal-title":"Br J Neurosurg"},{"issue":"26","key":"10.1016\/j.gendis.2016.10.002_bib14","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"issue":"230","key":"10.1016\/j.gendis.2016.10.002_bib15","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008002","article-title":"Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody","volume":"6","author":"Iwama","year":"2014","journal-title":"Sci Transl Med"},{"issue":"1","key":"10.1016\/j.gendis.2016.10.002_bib16","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s11102-015-0671-4","article-title":"Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights","volume":"19","author":"Faje","year":"2016","journal-title":"Pituitary"},{"issue":"3","key":"10.1016\/j.gendis.2016.10.002_bib17","doi-asserted-by":"crossref","first-page":"351","DOI":"10.4158\/EP11273.OR","article-title":"Association of ipilimumab therapy for advanced melanoma with secondary adrenal insufficiency: a case series","volume":"18","author":"Min","year":"2012","journal-title":"Endocr Pract"},{"issue":"17","key":"10.1016\/j.gendis.2016.10.002_bib18","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","article-title":"Immune checkpoint blockade in cancer therapy","volume":"33","author":"Postow","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.gendis.2016.10.002_bib19","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2147\/CMAR.S31873","article-title":"Characteristics and management of immunerelated adverse effects associated with ipilimumab, a new immunotherapy for metastatic melanoma","volume":"4","author":"Andrews","year":"2012","journal-title":"Cancer Manag Res"},{"issue":"2","key":"10.1016\/j.gendis.2016.10.002_bib20","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00280-013-2213-y","article-title":"Ipilimumab-induced endocrinopathies: when to start corticosteroids (or not)","volume":"72","author":"Corsello","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"issue":"7","key":"10.1016\/j.gendis.2016.10.002_bib21","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/S0092-8674(05)80055-8","article-title":"Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7\/BB1 in interleukin-2 production and immunotherapy","volume":"71","author":"Schwartz","year":"1992","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.gendis.2016.10.002_bib22","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S1074-7613(94)80021-9","article-title":"Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors","volume":"1","author":"Linsley","year":"1994","journal-title":"Immunity"},{"issue":"5795","key":"10.1016\/j.gendis.2016.10.002_bib23","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1126\/science.1131078","article-title":"Reversal of the TCR stop signal by CTLA-4","volume":"313","author":"Schneider","year":"2006","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.gendis.2016.10.002_bib24","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","author":"Freeman","year":"2000","journal-title":"J Exp Med"},{"issue":"12","key":"10.1016\/j.gendis.2016.10.002_bib25","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1038\/70932","article-title":"B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion","volume":"5","author":"Dong","year":"1999","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.gendis.2016.10.002_bib26","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/85330","article-title":"PD-L2 is a second ligand for PD-1 and inhibits T cell activation","volume":"2","author":"Latchman","year":"2001","journal-title":"Nat Immunol"},{"issue":"4","key":"10.1016\/j.gendis.2016.10.002_bib27","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1084\/jem.20051776","article-title":"Tissue expression of PD-L1 mediates peripheral T cell tolerance","volume":"203","author":"Keir","year":"2006","journal-title":"J Exp Med"},{"issue":"7","key":"10.1016\/j.gendis.2016.10.002_bib28","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1093\/intimm\/dxm057","article-title":"PD-1 and PD-1 ligands: from discovery to clinical application","volume":"19","author":"Okazaki","year":"2007","journal-title":"Int Immunol"},{"key":"10.1016\/j.gendis.2016.10.002_bib29","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"Keir","year":"2008","journal-title":"Annu Rev Immunol"},{"issue":"8","key":"10.1016\/j.gendis.2016.10.002_bib30","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nm730","article-title":"Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion","volume":"8","author":"Dong","year":"2002","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.gendis.2016.10.002_bib31","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1158\/0008-5472.CAN-03-3259","article-title":"PD-L1\/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells","volume":"64","author":"Blank","year":"2004","journal-title":"Cancer Res"},{"issue":"127","key":"10.1016\/j.gendis.2016.10.002_bib32","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003689","article-title":"Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape","volume":"4","author":"Taube","year":"2012","journal-title":"Sci Transl Med"},{"issue":"10031","key":"10.1016\/j.gendis.2016.10.002_bib33","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.gendis.2016.10.002_bib34","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1210\/jc.2014-4560","article-title":"Induction of painless thyroiditis in patients receiving programmed death 1 receptor immunotherapy for metastatic malignancies","volume":"100","author":"Orlov","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.gendis.2016.10.002_bib35","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1530\/EJE-10-0833","article-title":"Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy","volume":"164","author":"Min","year":"2011","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"10.1016\/j.gendis.2016.10.002_bib36","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1158\/2326-6066.CIR-13-0146","article-title":"Anti-PD1 following ipilimumab for mucosal melanoma: durable tumor response associated with severe hypothyroidism and rhabdomyolysis","volume":"2","author":"Min","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.gendis.2016.10.002_bib37","first-page":"2087525","article-title":"Treatment of ipilimumab induced Graves' disease in a patient with metastatic melanoma","volume":"2016","author":"Azmat","year":"2016","journal-title":"Case Rep Endocrinol"},{"key":"10.1016\/j.gendis.2016.10.002_bib38","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2016-214603","article-title":"A rare case of thyroid storm","volume":"2016","author":"McMillen","year":"2016","journal-title":"BMJ Case Rep"},{"issue":"11","key":"10.1016\/j.gendis.2016.10.002_bib39","doi-asserted-by":"crossref","first-page":"e182","DOI":"10.2337\/dc15-1331","article-title":"Anti-PD1 pembrolizumab can induce exceptional fulminant type 1 diabetes","volume":"38","author":"Gaudy","year":"2015","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.gendis.2016.10.002_bib40","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.2337\/dc14-2349","article-title":"Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy","volume":"38","author":"Hughes","year":"2015","journal-title":"Diabetes Care"},{"issue":"21","key":"10.1016\/j.gendis.2016.10.002_bib41","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma","volume":"372","author":"Postow","year":"2015","journal-title":"N Engl J Med"}],"container-title":["Genes & Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352304216300423?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352304216300423?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T21:15:44Z","timestamp":1749676544000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352304216300423"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["S2352304216300423"],"URL":"https:\/\/doi.org\/10.1016\/j.gendis.2016.10.002","relation":{},"ISSN":["2352-3042"],"issn-type":[{"type":"print","value":"2352-3042"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune-related endocrine disorders in novel immune checkpoint inhibition therapy","name":"articletitle","label":"Article Title"},{"value":"Genes & Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gendis.2016.10.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016, Chongqing Medical University. Production and hosting by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}